|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Interstitial Cystitis | |||||
| Bladder Diseases | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Cystitis | |||||
| Cystitis, Interstitial | |||||
| Syndrome | |||||
| Urinary Bladder Diseases | |||||
| 3 | More general conditions related to this trial | ||||
| Disease | |||||
| Pathologic Processes | |||||
| Urologic Diseases | |||||
| 4 | Interventions listed in this trial | ||||
| dimethyl sulfoxide | |||||
| IC Cocktail | |||||
| 5 | More general drug interventions related to this trial | ||||
| Antioxidants | |||||
| Cryoprotective Agents | |||||
| Free Radical Scavengers | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| Protective Agents | |||||
| 6 | Sponsors listed in this trial | ||||
| Capital District Health Authority, Canada | |||||